Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (12,769)

Search Parameters:
Keywords = clinical T2

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
18 pages, 9283 KiB  
Article
METTL3 Promotes Cutaneous T-Cell Lymphoma Progression by Regulating ARHGEF12 Expression
by Lu Gan, Yingqi Kong, Haoze Shi, Congcong Zhang, Cuicui Tian and Hao Chen
Int. J. Mol. Sci. 2025, 26(8), 3640; https://doi.org/10.3390/ijms26083640 (registering DOI) - 11 Apr 2025
Abstract
Recent studies have identified N6-methyladenosine (m6A) RNA methylation as a key regulatory mechanism in tumor progression. This study aimed to elucidate the biological function and clinical relevance of the m6A methyltransferase METTL3 in cutaneous T-cell lymphoma (CTCL). Our findings demonstrated that METTL3 expression [...] Read more.
Recent studies have identified N6-methyladenosine (m6A) RNA methylation as a key regulatory mechanism in tumor progression. This study aimed to elucidate the biological function and clinical relevance of the m6A methyltransferase METTL3 in cutaneous T-cell lymphoma (CTCL). Our findings demonstrated that METTL3 expression is upregulated in CTCL, and its knockdown suppresses CTCL progression. Mechanistically, the downregulation of METTL3-mediated m6A modification on ARHGEF12 mRNA accelerated its degradation, a process that is closely associated with tumor behaviors. These results suggest that METTL3 may serve as a potential therapeutic target in CTCL. Full article
(This article belongs to the Section Molecular Oncology)
16 pages, 1669 KiB  
Article
Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody
by Kanyarat Thongheang, Thanathat Pamonsupornwichit, Kanokporn Sornsuwan, On-anong Juntit, Tawan Chokepaichitkool, Weeraya Thongkum, Umpa Yasamut and Chatchai Tayapiwatana
Antibodies 2025, 14(2), 36; https://doi.org/10.3390/antib14020036 (registering DOI) - 11 Apr 2025
Abstract
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with high metastatic potential, poor prognosis, and the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). The lack of these receptors limits the standard treatments, such as hormone [...] Read more.
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype with high metastatic potential, poor prognosis, and the absence of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). The lack of these receptors limits the standard treatments, such as hormone therapies and HER2-targeted antibodies like trastuzumab. These challenges highlight the critical need for novel therapeutic strategies. CD147, a transmembrane glycoprotein overexpressed in TNBC, promotes tumor progression, metastasis, and chemoresistance, making it a promising therapeutic target. This study evaluates the antibody-dependent cellular cytotoxicity (ADCC) of HuM6-1B9, a humanized anti-CD147 antibody, against MDA-MB-231 cells, a TNBC model. Methods: CFSE-labelled MDA-MB-231 cells were co-cultured with PBMCs as effector cells (E:T ratio 80:1) in the presence of HuM6-1B9 and incubated for 4 h. Cells were then collected and stained with PI, and CFSE+/PI+ dead target cells were analyzed by flow cytometry. Results: Co-culturing MDA-MB-231 cells with peripheral blood mononuclear cells (PBMCs) in the presence of HuM6-1B9 demonstrated effective ADCC induction without direct cytotoxicity. HuM6-1B9 induced 54.01% cancer cell death via ADCC, significantly outperforming trastuzumab (26.14%) while sparing PBMCs. Conclusion: These findings support HuM6-1B9 as a prospective TNBC therapeutic and warrant further investigation into its clinical potential. Full article
11 pages, 1037 KiB  
Article
Clinical Evaluation of Body Composition, Diet, and Physical Activity in Type 1 Diabetes: A Controlled Cross-Sectional Study
by Isaki Hanamura, Ryoko Hongo, Norio Abiru and Nobuko Sera
Diabetology 2025, 6(4), 29; https://doi.org/10.3390/diabetology6040029 - 11 Apr 2025
Abstract
Background: This study examined differences in body composition, dietary intake, and exercise habits between people with type 1 diabetes (T1DM) and those without diabetes (NDM). We also sought to clarify the clinical and lifestyle characteristics of overweight people with T1DM. Methods: This controlled [...] Read more.
Background: This study examined differences in body composition, dietary intake, and exercise habits between people with type 1 diabetes (T1DM) and those without diabetes (NDM). We also sought to clarify the clinical and lifestyle characteristics of overweight people with T1DM. Methods: This controlled cross-sectional study was conducted at a single center, and included 45 people with T1DM and 50 NDM individuals. Body composition, nutrient intake, and exercise habits were evaluated, and exercise habits were compared between people with a T1DM onset before 20 years of age and those with an onset at or after 20 years of age, in relation to the NDM group. Overweight was defined using a BMI of 25.0 kg/m2 as the cutoff. Results: The T1DM group had significantly higher BMI and body fat than the NDM group, but no significant difference in muscle mass, and consumed a higher percentage of carbohydrates and a lower percentage of fat. The early-onset T1DM group had significantly lower exercise habits during their school years and in their current life than the NDM group. Individuals in the overweight T1DM group had a lower time in range on a continuous glucose monitor and a higher carbohydrate intake than those in the non-overweight T1DM group. Conclusions: The study suggested that the T1DM group had a significantly higher body fat percentage and carbohydrate intake, and significantly reduced exercise habits as students, compared to the NDM group. Full article
Show Figures

Figure 1

8 pages, 854 KiB  
Article
Co-Colonization of Non-difficile Clostridial Species in Antibiotic-Associated Diarrhea Caused by Clostridioides difficile
by Daniel Salas-Treviño, Samantha Flores-Treviño, Carlos Cisneros-Rendón, Cristian Valdemar Domínguez-Rivera and Adrián Camacho-Ortiz
Antibiotics 2025, 14(4), 397; https://doi.org/10.3390/antibiotics14040397 - 11 Apr 2025
Abstract
Background/Objectives: Antibiotic-associated diarrhea (AAD) is a public health problem that develops in the hospital setting. The most common causative agent of AAD is Clostridioides difficile infection (CDI), although other non-difficile Clostridia (NDC) might also be present. NDC include members of the [...] Read more.
Background/Objectives: Antibiotic-associated diarrhea (AAD) is a public health problem that develops in the hospital setting. The most common causative agent of AAD is Clostridioides difficile infection (CDI), although other non-difficile Clostridia (NDC) might also be present. NDC include members of the RIC group such as Clostridium ramosum [T. ramosa], Clostridium innocuum and Clostridium clostridioforme [E. clostridioformis]. The co-colonization of NDC and CDI in patients with AAD has not been fully analyzed. Methods: We compared clinical and laboratory data of patients with C. difficile infection (CDI) plus NDC against patients with only CDI. This study was a retrospective, case–control study. Hospitalized confirmed CDI cases were analyzed. CDI detection was performed using a 2-step diagnostic algorithm, including glutamate dehydrogenase (GDH) with toxin A/toxin B assays and molecular detection of the tpi gene. Stool samples were cultured and colonies morphologically compatible with any Clostridia were identified with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Fisher’s exact test and odds ratio (OR) were calculated to determine the degree of correlation between the variables and the study groups. Results: In the CDI + NDC group (n = 7), positive culture was observed for C. ramosum [T. ramosa] (n = 3), C. innocuum (n = 3), and C. butyricum (n = 1). According to our results, CDI + NDC patients received more days of antibiotic therapy, took more days to reduce diarrhea, had a significant increase in the number of days to suppress diarrhea, and previous hospitalizations were more frequently reported. Conclusions: In conclusion, the positive culture of NDC species such as C. innocuum or C. ramosum in patients with AAD caused by CDI correlates with treatment extension and/or failure. Full article
Show Figures

Figure 1

17 pages, 2758 KiB  
Article
Computed Tomography-Based Radiomic Nomogram to Predict Occult Pleural Metastasis in Lung Cancer
by Xiaoyi Zhao, Heng Zhao, Kongxu Dai, Xiangyu Zeng, Yun Li, Feng Yang and Guanchao Jiang
Curr. Oncol. 2025, 32(4), 223; https://doi.org/10.3390/curroncol32040223 - 11 Apr 2025
Abstract
Objectives: The preoperative identification of occult pleural metastasis (OPM) in lung cancer remains a crucial clinical challenge. This study aimed to develop and validate a predictive model that integrates clinical information with chest CT radiomic features to preoperatively identify patients at risk of [...] Read more.
Objectives: The preoperative identification of occult pleural metastasis (OPM) in lung cancer remains a crucial clinical challenge. This study aimed to develop and validate a predictive model that integrates clinical information with chest CT radiomic features to preoperatively identify patients at risk of OPM. Methods: This study included 50 patients diagnosed with OPM during surgery as the positive training cohort and an equal number of nonmetastatic patients as the negative control cohort. Using least absolute shrinkage and selection operator (LASSO) logistic regression, we identified key radiomic features and calculated radiomic scores. A predictive nomogram was developed by combining clinical characteristics and radiomic scores, which was subsequently validated with data from an additional 545 patients across three medical centers. Results: Univariate and multivariate logistic regression analyses revealed that carcinoembryonic antigen (CEA), the neutrophil-to-lymphocyte ratio (NLR), the clinical T stage, and the tumor–pleural relationship were significant clinical predictors. The clinical model alone achieved an area under the curve (AUC) of 0.761. The optimal integrated model, which combined radiomic scores from the volume of interest (VOI) with the CEA and NLR, demonstrated an improved predictive performance, with AUCs of 0.890 in the training cohort and 0.855 in the validation cohort. Conclusions: Radiomic features derived from CT scans show significant promise in identifying patients with lung cancer at risk of OPM. The nomogram developed in this study, which integrates CEA, the NLR, and radiomic tumor area scores, enhances the precision of preoperative OPM prediction and provides a valuable tool for clinical decision-making. Full article
(This article belongs to the Section Thoracic Oncology)
Show Figures

Figure 1

11 pages, 460 KiB  
Article
Type 1 Diabetes/Hidradenitis Suppurativa Comorbidity—A Population-Based Study
by Shany Sherman, Ron Slama, Danielle Bar, Yochai Schonmann, Arnon D. Cohen, Yossef H. Taieb, Daniel Mimouni, Alon Peretz and Hadar Duskin-Bitan
J. Clin. Med. 2025, 14(8), 2625; https://doi.org/10.3390/jcm14082625 - 11 Apr 2025
Abstract
Background: Type 1 diabetes (T1D) and hidradenitis suppurativa (HS) share several metabolic and inflammatory dysfunctions. Prior studies of the potential link between the diseases either lacked validated T1D diagnoses or established only an indirect association. This study sought to determine the odds [...] Read more.
Background: Type 1 diabetes (T1D) and hidradenitis suppurativa (HS) share several metabolic and inflammatory dysfunctions. Prior studies of the potential link between the diseases either lacked validated T1D diagnoses or established only an indirect association. This study sought to determine the odds of HS developing in patients with a validated diagnosis of T1D and to characterize the clinical features of HS/T1D comorbidity. Methods: A population-based nested case-control study was conducted including patients with HS and controls matched 5:1 for age, sex, and primary care clinic. T1D was diagnosed using a specialized algorithm, achieving 90% accuracy. Diagnostic validity was confirmed by diabetes specialists who manually reviewed a random subset of the files. Unadjusted and adjusted odds ratios (OR/aOR) were calculated to determine the odds of incident HS in patients with T1D. Results: The study included 10,919 patients with HS and 53,314 controls. A history of T1D was associated with an elevated odds of new-onset HS (OR 1.80 95% CI (1.30–2.40), p < 0.001), even after adjusting for demographics and metabolic and autoimmune comorbidities (aORs > 1.7, p < 0.001). Patients with HS/T1D comorbidity had higher proportions of autoimmune conditions than patients with HS alone (p < 0.001) and a higher mean Charlson Comorbidity Index score than both patients with HS alone (3.5 vs. 0.9, p < 0.001) and T1D alone (3.5 vs. 2.2, p = 0.004). Conclusions: T1D is associated with higher odds of the subsequent development of HS. Awareness of HS/T1D comorbidity is recommended owing to the elevated burden of metabolic and autoimmune conditions. Full article
(This article belongs to the Special Issue Autoimmune Skin Diseases: Innovations, Challenges, and Opportunities)
Show Figures

Figure 1

16 pages, 3351 KiB  
Article
Immunomodulatory Effects of Curcumin on CAR T-Cell Therapy
by Praopim Limsakul, Pemikar Srifa, Ziliang Huang, Linshan Zhu, Yiqian Wu and Krit Charupanit
Antioxidants 2025, 14(4), 454; https://doi.org/10.3390/antiox14040454 - 10 Apr 2025
Viewed by 98
Abstract
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies, demonstrating high efficacy in targeting and eliminating cancer cells. However, its clinical application can be associated with the risk of acute adverse effects, including cytokine release syndrome (CRS), a severe [...] Read more.
Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of hematological malignancies, demonstrating high efficacy in targeting and eliminating cancer cells. However, its clinical application can be associated with the risk of acute adverse effects, including cytokine release syndrome (CRS), a severe inflammatory response caused by excessive cytokine production. While anti-cytokine therapies are available to manage CRS, additional strategies are needed to optimize CAR T-cell efficacy with reduced toxicities. Curcumin, a bioactive polyphenol known for its anti-inflammatory and antioxidant properties, represents a promising adjunct for CAR T-cell therapy. In this study, we investigated the effects of curcumin on anti-CD19 CAR T-cells in vitro. Our results show that curcumin enhances the cytotoxic activity of CAR T-cells against Nalm-6, a B-cell acute lymphoblastic leukemia model, while reducing the production of pro-inflammatory cytokines, including IL-2 and IFN-γ. To explore its underlying mechanisms, network pharmacology and molecular docking analyses were performed, which revealed that curcumin interacts with key signaling pathways involved in T-cell activation and cytokine regulation. These findings support the potential of curcumin as a therapeutic adjunct to improve CAR T-cell efficacy while mitigating inflammatory toxicity. Full article
Show Figures

Figure 1

15 pages, 2424 KiB  
Article
Prognostic Value of Biomarkers in COVID-19: Associations with Disease Severity, Viral Variants, and Comorbidities—A Retrospective Observational Single-Center Cohort Study
by Zoran Barušić, Kristian Bodulić, Sanja Zember, Renata Laškaj, Rok Čivljak, Ivan Puljiz, Ivan-Christian Kurolt, Željka Mačak Šafranko, Lidija Cvetko Krajinović, Petra Svoboda Karić and Alemka Markotić
Life 2025, 15(4), 634; https://doi.org/10.3390/life15040634 - 10 Apr 2025
Viewed by 39
Abstract
Coronavirus disease (COVID-19) exhibits a wide spectrum of clinical severity and has been associated with specific biomarkers linked to disease progression and outcomes. This retrospective study analyzed sera from 1222 adult COVID-19 patients hospitalized at the University Hospital for Infectious Diseases in Croatia. [...] Read more.
Coronavirus disease (COVID-19) exhibits a wide spectrum of clinical severity and has been associated with specific biomarkers linked to disease progression and outcomes. This retrospective study analyzed sera from 1222 adult COVID-19 patients hospitalized at the University Hospital for Infectious Diseases in Croatia. We examined the association between several laboratory biomarker levels measured at patient admission and disease severity, fatal outcomes, viral variants and clinical parameters. Deceased patients and surviving patients with severe COVID-19 exhibited significantly elevated levels of several biomarkers on admission, including hs-troponin T, N-terminal pro-brain natriuretic peptide, creatine kinase, C-reactive protein, procalcitonin, interleukin-6, lactate dehydrogenase, lactate, urea and creatinine. Random forest models identified lymphocyte percentage, D-dimers, and hs-troponin T as the most important biomarkers for fatal outcome prediction, achieving 84.1% accuracy. Patients infected with the Delta SARS-CoV-2 variant exhibited significantly higher levels of proinflammatory, cardiac and renal biomarkers. Vaccination correlated with reduced proinflammatory parameters and higher lymphocyte proportions. Hypertension, chronic renal disease and diabetes were associated with increased cardiac, renal and metabolic biomarker levels, respectively. These findings highlight the association of several laboratory biomarkers with COVID-19 severity, viral variants, vaccination status and comorbidities, potentially offering prognostic insights into COVID-19 outcomes. Full article
Show Figures

Figure 1

18 pages, 2489 KiB  
Article
Evaluation of the Biolabo Turbidimetric Assay for Automated Determination of Haemoglobin A1c
by Lorenza Fagnani, Simonetta De Angelis, Pierangelo Bellio, Patrizia Frascaria, Rita Tennina, Giovanni Alloggia, Francesco Gentile, Alessandra Piccirilli, Mariagrazia Perilli and Giuseppe Celenza
Diagnostics 2025, 15(8), 969; https://doi.org/10.3390/diagnostics15080969 - 10 Apr 2025
Viewed by 49
Abstract
Background/Objectives: The determination of glycated haemoglobin (HbA1c) is a cornerstone of the diagnosis and management of diabetes mellitus, serving as a reliable biomarker for assessing long-term glycaemic control. While high-performance liquid chromatography (HPLC) is regarded as the gold standard for HbA1c measurement, [...] Read more.
Background/Objectives: The determination of glycated haemoglobin (HbA1c) is a cornerstone of the diagnosis and management of diabetes mellitus, serving as a reliable biomarker for assessing long-term glycaemic control. While high-performance liquid chromatography (HPLC) is regarded as the gold standard for HbA1c measurement, its widespread adoption is limited by high costs, operational complexity, and resource requirements. Alternative methodologies, including immunoturbidimetric assays, have garnered interest as practical solutions. This study evaluates the analytical performance of an immunoturbidimetric method for HbA1c determination and its comparability with a validated HPLC method. Methods: The evaluation process was conducted in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The results from 178 human sample leftovers, covering the medical decision range, were compared with those obtained using the HPLC-based Menarini ADAMS A1c HA-8180T system. The analytical performance regarding repeatability and within-laboratory imprecision was also assessed. The probability risk of misinterpreting the analytical results was also calculated. Results: The Passing–Bablok regression indicated a strong correlation between the two methods, with a slope of 1.00 (95% CI: 1.00 to 1.04). The Bland–Altman analysis confirmed minimal systematic differences, showing a mean bias of −0.07% for NGSP and −0.74 mmol/mol for IFCC, both falling within the predefined total allowable error (ATE) limits. Imprecision studies demonstrated excellent repeatability and intermediate precision, with coefficients of variation (CV) ranging from 0.68% to 2.4% across all levels. The risk assessment of diagnostic misinterpretation indicated minimal deviation from an ideal analytical system, in which the measurement uncertainty was regarded as zero. Conclusions: The findings establish the immunoturbidimetric method as a reliable and cost-effective alternative to HPLC for routine HbA1c determination. Its strong analytical performance, combined with operational efficiency, makes it a valuable tool for laboratories, particularly in resource-limited settings, enhancing access to high-quality diabetes monitoring. Full article
(This article belongs to the Special Issue Advances in the Laboratory Diagnosis)
Show Figures

Figure 1

23 pages, 3375 KiB  
Article
Synergistic HDAC4/8 Inhibition Sensitizes Osteosarcoma to Doxorubicin via pAKT/RUNX2 Pathway Modulation
by Anuja Gajanan Magar, Vivek Kumar Morya, Young-Ho Koh and Kyu-Cheol Noh
Int. J. Mol. Sci. 2025, 26(8), 3574; https://doi.org/10.3390/ijms26083574 - 10 Apr 2025
Viewed by 37
Abstract
Osteosarcoma is a highly aggressive bone malignancy, particularly challenging in metastatic cases, with a 5-year survival rate remaining under 30%. Although doxorubicin (doxo) is a standard first-line chemotherapeutic agent, its clinical utility is often hindered by the development of drug resistance and associated [...] Read more.
Osteosarcoma is a highly aggressive bone malignancy, particularly challenging in metastatic cases, with a 5-year survival rate remaining under 30%. Although doxorubicin (doxo) is a standard first-line chemotherapeutic agent, its clinical utility is often hindered by the development of drug resistance and associated systemic toxicity. Emerging evidence highlights the role of epigenetic alterations, particularly those involving histone deacetylases (HDACs), in promoting chemoresistance. In this context, the present study aimed to evaluate the therapeutic potential of combining doxo with the selective HDAC inhibitors, tasquinimod (Tas, targeting HDAC4) and PCI-34051 (PCI, targeting HDAC8), in SJSA-1 osteosarcoma cells. Utilizing both 2D and 3D in vitro models, the combination treatment (referred to as the T4 group) significantly reduced cell viability by 57.69% in 2D cultures and decreased spheroid volume by 35.19% in 3D models. The apoptotic response was markedly enhanced, with late apoptosis reaching 64.59% and necrosis at 32.07%, both surpassing the effects observed with doxo alone. Furthermore, wound healing assays demonstrated a 37.74% inhibition of migration, accompanied by a decreased expression of the matrix metalloproteinases MMP9 and MMP13. Mechanistically, the combination therapy led to the downregulation of protein kinase B (pAKT) and RUNX2, along with upregulation of apoptotic markers, including caspase 8, caspase 3, and cleaved caspase 3, indicating a disruption of key survival pathways. These findings suggest that dual HDAC inhibition with Tas and PCI can potentiate doxo efficacy by enhancing apoptosis, inhibiting proliferation, and reducing metastatic potential, thus offering a promising strategy to overcome chemoresistance in osteosarcoma. Further preclinical and clinical studies are required to validate these therapeutic benefits. Full article
Show Figures

Figure 1

12 pages, 234 KiB  
Article
Impact of 10 Weeks of Yoga Intervention on Mental Health and Overall Well-Being Among Medical Students: GSY Study
by Shalini Chauhan, Sachal Sadiq Najaf, Lukács Gergely, Király Anita Kinga, István Karsai and Viktoria Prémusz
Sports 2025, 13(4), 114; https://doi.org/10.3390/sports13040114 - 10 Apr 2025
Viewed by 51
Abstract
Background: the purpose of this study was to explore the effect of 10 weeks of yoga intervention on the mental health outcomes (stress, anxiety, and depression), quality of life, emotional regulation, and quality of sleep of medical students. Method: In the current experimental [...] Read more.
Background: the purpose of this study was to explore the effect of 10 weeks of yoga intervention on the mental health outcomes (stress, anxiety, and depression), quality of life, emotional regulation, and quality of sleep of medical students. Method: In the current experimental study, 220 medical students, with a mean age of 21.36 ± 2.20 years, participated in a 10-week yoga intervention at the University of Pécs. Data were collected before and after the intervention using the validated questionnaires DASS-21, WHOQOL-BREF, PSQI, and DERS. The distribution of data was checked using the Kolmogorov–Smirnov test. A paired sample T-test was used to compare the mean of the continuous variable. Stepwise linear regression was used to assess the association between mental health outcomes and quality-of-life variables. Results: The present study shows a significant reduction in (p < 0.001), depression (p < 0.001), and anxiety (p < 0.001) for participants, and overall quality of life (p < 0.001), quality of sleep (p < 0.001), and emotional regulation (p < 0.001) significantly improved after the intervention. The stepwise linear regression shows a strong association between higher levels of anxiety (β = 0.608, R2 = 0.366) and depression (β = 0.608, R2 = 0.392), with higher stress levels and improvement in environmental conditions being associated with a decrease in stress levels (β = −0.392, R2 = 0.087). Conclusions: the current study shows that yoga significantly improved the mental health and well-being of medical students, improving quality of life, quality of sleep, and emotional regulation. Registered Clinical Trial: NCT06661603. Full article
20 pages, 1951 KiB  
Review
Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions
by Lilian Fernandes Silva and Markku Laakso
Int. J. Mol. Sci. 2025, 26(8), 3572; https://doi.org/10.3390/ijms26083572 - 10 Apr 2025
Viewed by 60
Abstract
Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding the metabolic disturbances related to these disorders. Recent advances toward the integration of metabolomics into clinical [...] Read more.
Type 2 diabetes (T2D) and cardiovascular diseases (CVDs) are major public health challenges worldwide. Metabolomics, the exhaustive assessment of metabolites in biological systems, offers important insights regarding the metabolic disturbances related to these disorders. Recent advances toward the integration of metabolomics into clinical practice to facilitate the discovery of novel biomarkers that can improve the diagnosis, prognosis, and treatment of T2D and CVDs are discussed in this review. Metabolomics offers the potential to characterize the key metabolic alterations associated with disease pathophysiology and treatment. T2D is a heterogeneous disease that develops through diverse pathophysiological processes and molecular mechanisms; therefore, the disease-causing pathways of T2D are not completely understood. Recent studies have identified several robust clusters of T2D variants representing biologically meaningful, distinct pathways, such as the beta cell and proinsulin cluster related to pancreatic insulin secretion, obesity, lipodystrophy, the liver/lipid cluster, glycemia, and blood pressure, and metabolic syndrome clusters representing different pathways causing insulin resistance. Regarding CVDs, recent studies have allowed the metabolomic profile to delineate pathways that contribute to atherosclerosis and heart failure, as well as to the development of targeted therapy. This review also covers the role of metabolomics in integrated metabolic genomics and other omics platforms to better understand disease mechanisms, along with the transition toward precision medicine. This review further investigates the use of metabolomics in multi-metabolite modeling to enhance risk prediction models for predicting the first occurrence of major adverse cardiovascular events among individuals with T2D, highlighting the value of such approaches in optimizing the preventive and therapeutic models used in clinical practice. Full article
(This article belongs to the Special Issue Research Progress of Metabolomics in Health and Disease)
Show Figures

Figure 1

45 pages, 4152 KiB  
Review
Connecting the Dots: How MicroRNAs Link Asthma and Atherosclerosis
by Răzvan-Ionuț Zimbru, Elena-Larisa Zimbru, Florina-Maria Bojin, Laura Haidar, Minodora Andor, Octavia Oana Harich, Gabriela Tănasie, Carmen Tatu, Diana-Evelyne Mailat, Iulia-Maria Zbîrcea, Bogdan Hirtie, Cristina Uța, Camelia-Felicia Bănărescu and Carmen Panaitescu
Int. J. Mol. Sci. 2025, 26(8), 3570; https://doi.org/10.3390/ijms26083570 - 10 Apr 2025
Viewed by 178
Abstract
Asthma and atherosclerosis are chronic conditions with distinct pathophysiologies, but overlapping inflammatory mechanisms that suggest a potential common regulatory framework. MicroRNAs (miRNAs), small non-coding RNA molecules that modulate gene expression post-transcriptionally, could be key players in linking these disorders. This review outlines how [...] Read more.
Asthma and atherosclerosis are chronic conditions with distinct pathophysiologies, but overlapping inflammatory mechanisms that suggest a potential common regulatory framework. MicroRNAs (miRNAs), small non-coding RNA molecules that modulate gene expression post-transcriptionally, could be key players in linking these disorders. This review outlines how miRNAs contribute to the complex interplay between asthma and atherosclerosis, focusing on key miRNAs involved in inflammatory pathways, immune cell regulation and vascular remodeling. We discuss specific miRNAs, such as miR-155, miR-21 and miR-146a, which have been shown to modulate inflammatory cytokine production and T cell differentiation, impacting respiratory and cardiovascular health. The common miRNAs found in both asthma and atherosclerosis emphasize their role as potential biomarkers, but also as therapeutic targets. Understanding these molecular connections may unlock novel approaches for innovative, integrated treatment strategies that address both conditions and may significantly improve patient outcomes. Further research is needed to explore mechanistic pathways and validate the translational potential of miRNA-based interventions in preclinical and clinical settings. Full article
(This article belongs to the Special Issue Recent Advances in RNA Drug Development)
Show Figures

Figure 1

11 pages, 787 KiB  
Article
Lymphopenia as an Independent Marker of Disease Activity in Children with Systemic Lupus Erythematosus
by Gartika Sapartini, Reni Ghrahani and Budi Setiabudiawan
Children 2025, 12(4), 486; https://doi.org/10.3390/children12040486 - 10 Apr 2025
Viewed by 38
Abstract
Background: Lymphopenia is associated with disease activity in adult patients with systemic lupus erythematosus (SLE), but no similar studies exist among children. Furthermore, lymphopenia has only been used as a parameter of disease activity in the SLE disease activity index (SLEDAI), but [...] Read more.
Background: Lymphopenia is associated with disease activity in adult patients with systemic lupus erythematosus (SLE), but no similar studies exist among children. Furthermore, lymphopenia has only been used as a parameter of disease activity in the SLE disease activity index (SLEDAI), but not as an independent marker. Objectives: This study aimed to ascertain lymphopenia as an independent marker related to disease activity in children with SLE. Methods: This was a retrospective cohort study on patients newly diagnosed with SLE. The data were collected from January 2009 to March 2017, including clinical manifestations, complete blood counts, anti-dsDNA, and Mexican-SLEDAI (MEX-SLEDAI) scores. Statistical analysis was performed using the Chi-square test, Student’s t-test, and ROC curve analysis. Results: A total of 103 patients, aged from 12 to 18 years, participated in the study. Of these, 58 patients (56.3%) exhibited lymphopenia. The most commonly observed clinical manifestations in the lymphopenia group included nephritis (72.4%), hypertension (24.1%), and leukopenia (36.2%), with p < 0.05. Furthermore, neuropsychiatric SLE was found exclusively in the lymphopenia group. A negative correlation was observed between lymphocyte counts and anti-dsDNA levels (r = −0.24), as well as between lymphocyte counts and the MEX-SLEDAI score (r = −0.63, with p < 0.05). The receiver operating characteristic (ROC) curve indicated that a lymphocyte count with a cut-off point of ≤1738/mm3 is significant for predicting anti-dsDNA reactivity. Conclusions: Lymphopenia is significantly correlated with higher anti-dsDNA levels and increased disease activity, potentially serving as an independent marker of disease activity in children with SLE. However, further research is needed. Full article
(This article belongs to the Section Pediatric Allergy and Immunology)
Show Figures

Figure 1

32 pages, 1899 KiB  
Review
Advances in Gene Therapy with Oncolytic Viruses and CAR-T Cells and Therapy-Related Groups
by Yasunari Matsuzaka and Ryu Yashiro
Curr. Issues Mol. Biol. 2025, 47(4), 268; https://doi.org/10.3390/cimb47040268 - 10 Apr 2025
Viewed by 74
Abstract
Cancer gene therapy is attracting considerable attention as a new treatment method for overcoming intractable cancers. CAR-T cell therapy has already achieved remarkable results, particularly for hematological tumors. Because CAR-T cells can increase within the body, they have the advantage of requiring only [...] Read more.
Cancer gene therapy is attracting considerable attention as a new treatment method for overcoming intractable cancers. CAR-T cell therapy has already achieved remarkable results, particularly for hematological tumors. Because CAR-T cells can increase within the body, they have the advantage of requiring only a single administration. In addition, CAR-T cell therapy targeting the CD19 antigen has been established for relapsed or refractory disease in young people with CD19-positive acute B-cell leukemia (B-acute lymphoblastic leukemia, B-ALL) and diffuse large B-cell lymphoma (DLBCL). In addition to CAR-T cell therapy, oncolytic viruses represent a promising approach for cancer treatment, with some already in clinical use and others being researched for their potential benefits. These viruses infect and kill cancer cells, triggering an immune response that helps the body recognize and fight cancer. Oncolytic virus therapy is a form of immunotherapy that uses modified viruses to target and destroy tumor cells while potentially stimulating antitumor immune responses. These viruses have shown promising activity in clinical trials, with some approved for specific cancers like melanoma. Research is ongoing to improve their efficacy, expand their use to other cancer types, and overcome the logistical challenges associated with their delivery. Gene therapy can potentially treat diseases caused by recessive gene disorders like cystic fibrosis, hemophilia, muscular dystrophy, and sickle cell anemia, as well as acquired genetic diseases, such as cancer and viral infections like acquired immunodeficiency syndrome (AIDS). Full article
(This article belongs to the Special Issue New Immunological Therapeutic Strategies in Kidney Disease)
Show Figures

Figure 1

Back to TopTop